Frankfurt
08.09.25 | 15:29
7,600 Euro
+4,83 % +0,350
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 13 | Investing.com | ||
| 14.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 337 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | 234 | GlobeNewswire (Europe) | MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value... ► Artikel lesen | |
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 15.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 346 | GlobeNewswire (Europe) | Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint... ► Artikel lesen | |
| 16.04. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Fortress Biotech, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights | 120 | GlobeNewswire (Europe) | Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary... ► Artikel lesen | |
| 25.03. | Fortress Biotech FY 2024 Earnings Preview | 2 | Seeking Alpha | ||
| 17.03. | Fortress Biotech kooperiert mit Partex für KI-gestützte Arzneimittelentwicklung | 7 | Investing.com Deutsch | ||
| 17.03. | Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform | 210 | GlobeNewswire (Europe) | FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic... ► Artikel lesen | |
| 27.01. | Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT | 237 | GlobeNewswire (Europe) | Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the... ► Artikel lesen | |
| 06.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease | 345 | GlobeNewswire (Europe) | Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones... ► Artikel lesen | |
| 14.11.24 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 278 | GlobeNewswire (Europe) | Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 332,30 | -0,75 % | Stryker-Aktie: Kurs heute im Minus (333,8226 €) | Am US-amerikanischen Aktienmarkt notiert das Wertpapier von Stryker derzeit leichter. Zuletzt zahlten Investoren für das Wertpapier 388,92 US-Dollar. Ein Kursabschlag in Höhe von 2,49 US-Dollar müssen... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 474,50 | -3,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 05.09.2025 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,690 | -5,80 % | Down 34%, Should You Buy the Dip on Viking Therapeutics? | ||
| INTELLIA THERAPEUTICS | 10,260 | -0,29 % | Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia | ||
| TEMPUS AI | 68,00 | 0,00 % | What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum? | ||
| NUREXONE BIOLOGIC | 0,504 | -1,18 % | NurExone Biologic: Im Rampenlicht der Fachpresse! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,085 | +0,41 % | PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq | ||
| GINKGO BIOWORKS | 9,350 | -1,58 % | Ginkgo Bioworks enters into $100M equity sales deal | ||
| IOVANCE BIOTHERAPEUTICS | 2,064 | -3,08 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,625 | +0,33 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,778 | -8,44 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,985 | +0,17 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| BIOMEA FUSION | 1,805 | -5,99 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 6,150 | -0,81 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions | Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment... ► Artikel lesen | |
| BIONTECH | 87,45 | -8,91 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,350 (+4,83 %) liegt der Kurs bei 7,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.